District Court Denies Motion to Dismiss After Defendants Fail to Show Plaintiffs’ Diagnostic Claims Lacked an Inventive Concept

Sep 9, 2016

Reading Time : 2 min

The plaintiffs, Athena Diagnostics, Inc., Isis Innovation Ltd. and Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., developed and patented a method for diagnosing patients with the autoimmune disorder Myasthenia Gravis. The majority of patients with Myasthenia Gravis produce antibodies that attack their acetyl choline receptors, which causes the patients to experience waning muscle strength throughout the day. These patients are typically diagnosed by tests that detect the presence of autoantibodies to acetyl choline receptors. Approximately 20 percent of patients suffering from Myasthenia Gravis, however, do not produce acetyl choline receptor autoantibodies. The inventors of the patent asserted in this case discovered that Myasthenia Gravis patients who do not produce autoantibodies to acetyl choline receptors instead produce IgG antibodies that attack the N-terminal domains of muscle specific tyrosine kinase (“MuSK”), a receptor that is located on the surface of neuromuscular junctions. Relying on this discovery, the inventors developed an alternative method for diagnosing Myasthenia Gravis based on the detection of MuSK-specific autoantibodies. The claimed diagnostic methods are performed by attaching a radioactive isotope to the MuSK receptor protein or fragments thereof, introducing it into a sample of body fluid, and then detecting the presence of any antibody-antigen complexes formed between the radiolabeled receptor and antibodies present in the body fluid.

Defendants moved to dismiss plaintiffs’ complaint for infringement, alleging that the asserted patent claimed a law of nature, namely that certain Myasthenia Gravis patients produce autoantibodies to MuSK. Defendants further alleged that the asserted claims lack an inventive concept because they utilize standard techniques well-known in the art to perform the diagnostic method. Plaintiffs argued that the radiolabeled MuSK protein used in their methods is not a naturally occurring protein, and consequently, the claims are not directed to a law of nature. Plaintiffs also argued that utilizing a non-naturally occurring protein in a combination of known procedures transforms the claims and makes them patent eligible.

Under the first step of the Alice test, the district court rejected the plaintiffs’ assertion that their claims were patent eligible because they include the use of a radiolabeled compound that is not naturally occurring. Instead, the district court described the focus of the diagnostic methods to be the interaction of radiolabeled MuSK and patient body fluid, and held the interaction of these molecules to be naturally occurring. Turning to step two of the Alice test, the district court held that it could not determine whether the claims of the asserted patent contained an inventive concept that transformed them into patent eligible subject matter. Specifically, the district court stated that it could not determine at the motion to dismiss stage whether the combinations of steps claimed in the asserted patents were merely a series of techniques standard in the art or whether they were sufficiently inventive to deserve patent protection because it would be required to make factual determinations that went beyond what was apparent on the face of the complaint.

Athena Diagnostics, Inc. v. Mayo Collaborative Servs., LLC, C.A. No. 15-cv.40075-IT (D. Mass. Aug. 25, 2016).

Share This Insight

Previous Entries

IP Newsflash

May 30, 2025

A district court recently dismissed a patent infringement complaint for improper venue under 28 U.S.C. § 1400(b), finding that the storage and distribution of
products from an Amazon warehouse was not sufficient to establish that warehouse as a regular and established place of business in the district.
...

Read More

IP Newsflash

May 27, 2025

The Federal Circuit affirmed a District of Delaware finding of non-infringement in an ANDA litigation due to the patentee’s clear and unmistakable disavowal
of claim scope during prosecution. Specifically, the court held that statements made during prosecution of a parent application before the asserted claims
were allowed amounted to a prosecution disclaimer that extended to subsequent patents in the family. In reaching this conclusion, the court rejected an
attempt by the patentee to resurrect the claim scope through a unilateral, self-serving statement made in later applications in the family.
...

Read More

IP Newsflash

May 13, 2025

The Federal Circuit recently affirmed a district court’s holding that patent term extension (PTE) for a reissued patent was properly based on the issue date of
the original patent and not that of the reissued patent. The Federal Circuit concluded that, where both the original and reissued patents claimed a drug
product under regulatory review, using the issue date of the original patent to calculate PTE comports with both the purpose of the Hatch-Waxman Act and
the related statutory context.
...

Read More

IP Newsflash

May 12, 2025

The Patent Trial and Appeal Board recently declined to institute a petition for IPR that was filed on the same day that the petitioner filed another petition
challenging the same claims of the same patent. The board was not persuaded by petitioner’s arguments that a second petition was needed due to alleged
claim construction issues or the number, length or scope differences of the challenged claims.
...

Read More

IP Newsflash

May 9, 2025

The USPTO Director vacated the board’s decision to institute inter partes review based on an erroneous application of the Fintiv factors. Specifically, the
Director found that the board placed too much emphasis on Petitioner’s Sotera stipulation, and not enough emphasis on the investment in the parallel
litigation. Weighing the factors as a whole, the Director determined that institution should be denied.
...

Read More

IP Newsflash

May 9, 2025

In an institution decision following the USPTO’s withdrawal of its Fintiv Memo, the board addressed discretionary denial of an IPR under Fintiv in view of a
parallel ITC investigation. The board noted it would not consider the now-rescinded June 2022 memo from then-director Vidal which instructed that the PTAB
would not deny institution of an IPR or PGR under Fintiv when the request is based on a parallel ITC investigation. The board conducted a Fintiv analysis in
view of the ITC investigation, but ultimately determined that discretionary denial was not warranted in this particular situation.
...

Read More

IP Newsflash

April 23, 2025

The Federal Circuit recently refused to apply collateral estoppel to claims of a patent asserted in district court litigation based on a Patent Trial and Appeal
Board (PTAB) decision finding similar claims from the same patent unpatentable because the PTAB applied a lower burden of proof than what is required to
invalidate claims in district court.
...

Read More

IP Newsflash

April 7, 2025

The Central District of California denied a defendant’s motion to dismiss or transfer plaintiff’s first-filed declaratory judgment action based on defendant’s
later-filed patent infringement suit in Wisconsin.  Though suit was seemingly imminent when defendant advised plaintiff it might be infringing defendant’s
patents, plaintiff responded by requesting a licensing agreement in lieu of litigation. The court found that plaintiff’s action was not anticipatory
forum-shopping litigation because plaintiff only filed suit after defendant neglected to respond to its licensing offer.
...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.